Androgen deprivation therapy (ADT) is the first-line treatment to metastatic prostate cancer (PCa). However, sustained expression and function of the androgen receptor (AR) gene contribute to the progression of castration resistant prostate cancers (CRPC). Additionally, tumors can adapt the PI3K/AKT survival pathway to escape ADT. Co-targeting AR and PI3K/AKT signaling has been proposed to be a more effective therapeutic means for CRPC patients. Many clinical trials are ongoing to test whether PI3K/AKT inhibitors are beneficial to PCa patients. However whether these inhibitors have any impacts on the expressions of full length AR (AR-FL) and its splice variant (AR-V7) remains unclear.Four human prostate cancer cell lines (LNCaP, LNCaP95, VC...
Understanding of the molecular mechanisms of prostate cancer has led to development of therapeutic s...
There is significant need to identify novel prostate cancer drug targets because current hormone the...
Prostate cancer (PCa) is the most common malignancy in American males. If diagnosed in early stages,...
<div><p>Background</p><p>Androgen deprivation therapy (ADT) is the first-line treatment to metastati...
Prostate cancer (PCa) is the most common cancer in men. The androgen receptor (AR) has a pivotal rol...
Treatment-induced neuroendocrine (NE) prostate cancer (t-NEPC) is an aggressive subtype of prostate ...
The progression to castration-resistant prostate cancer (CRPC) correlates with gain-of-function of t...
Prostate cancer (PCa) is the second most common malignancy among men in the world. Castration-resist...
The reduction in androgen synthesis and the blockade of the androgen receptor (AR) function by chemi...
The androgen receptor (AR) is a central driver of aggressive prostate cancer. After initial treatmen...
Androgen deprivation therapy (ADT) and androgen receptor (AR)-targeted therapy are the gold standard...
Cell line studies demonstrate that the PI3K/Akt pathway is upregulated in hormone-refractory prostat...
The androgen receptor (AR) plays a key role in progression to incurable androgen ablation–resistant ...
The mechanisms responsible for the switch of prostate cancer from androgen-sensitive (AS) to androge...
International audienceDeregulation of the PI3K-Akt-mTOR pathway plays a critical role in the develop...
Understanding of the molecular mechanisms of prostate cancer has led to development of therapeutic s...
There is significant need to identify novel prostate cancer drug targets because current hormone the...
Prostate cancer (PCa) is the most common malignancy in American males. If diagnosed in early stages,...
<div><p>Background</p><p>Androgen deprivation therapy (ADT) is the first-line treatment to metastati...
Prostate cancer (PCa) is the most common cancer in men. The androgen receptor (AR) has a pivotal rol...
Treatment-induced neuroendocrine (NE) prostate cancer (t-NEPC) is an aggressive subtype of prostate ...
The progression to castration-resistant prostate cancer (CRPC) correlates with gain-of-function of t...
Prostate cancer (PCa) is the second most common malignancy among men in the world. Castration-resist...
The reduction in androgen synthesis and the blockade of the androgen receptor (AR) function by chemi...
The androgen receptor (AR) is a central driver of aggressive prostate cancer. After initial treatmen...
Androgen deprivation therapy (ADT) and androgen receptor (AR)-targeted therapy are the gold standard...
Cell line studies demonstrate that the PI3K/Akt pathway is upregulated in hormone-refractory prostat...
The androgen receptor (AR) plays a key role in progression to incurable androgen ablation–resistant ...
The mechanisms responsible for the switch of prostate cancer from androgen-sensitive (AS) to androge...
International audienceDeregulation of the PI3K-Akt-mTOR pathway plays a critical role in the develop...
Understanding of the molecular mechanisms of prostate cancer has led to development of therapeutic s...
There is significant need to identify novel prostate cancer drug targets because current hormone the...
Prostate cancer (PCa) is the most common malignancy in American males. If diagnosed in early stages,...